Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches
Abstract Model‐based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two‐stage or joint modeling methods to leverage Phase I...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-06-01
|
| Col·lecció: | CPT: Pharmacometrics & Systems Pharmacology |
| Accés en línia: | https://doi.org/10.1002/psp4.13137 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|